GRAIL, Inc. (GRAL)
79.56
-2.98
(-3.62%)
USD |
NASDAQ |
Aug 26, 16:00
79.56
0.00 (0.00%)
After-Hours: 19:39
GRAIL Total Liabilities (Quarterly) : 301.03M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 301.03M |
| March 31, 2026 | 302.79M |
| December 31, 2025 | 600.24M |
| September 30, 2025 | 361.07M |
| June 30, 2025 | 387.91M |
| March 31, 2025 | 433.94M |
| December 31, 2024 | 638.99M |
| September 30, 2024 | 530.32M |
| June 30, 2024 | 574.51M |
| March 31, 2024 | 233.46M |
| December 31, 2023 | 910.74M |
| September 30, 2023 |
| Date | Value |
|---|---|
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | 117.54M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.641M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.844B |
| Shareholders Equity (Quarterly) | 2.543B |
| Debt to Equity Ratio | 0.0359 |
| Current Ratio | 10.95 |
| Net Debt Paydown Yield | -0.18% |